HC Wainwright Has Lowered Expectations for Mural Oncology (NASDAQ:MURA) Stock Price

Mural Oncology (NASDAQ:MURA) had its target price decreased by HC Wainwright from $18.00 to $6.00 in a research note issued to investors on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Mural Oncology’s Q1 2026 earnings at ($0.81) EPS, Q2 2026 earnings at ($0.86) EPS, Q3 2026 earnings at ($0.88) EPS, Q4 2026 earnings at ($0.77) EPS and FY2026 earnings at ($3.32) EPS.

MURA has been the topic of several other research reports. Morgan Stanley lowered Mural Oncology from an “overweight” rating to an “equal weight” rating in a research report on Tuesday. Jones Trading restated a “hold” rating on shares of Mural Oncology in a report on Tuesday. Finally, Raymond James cut Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 price target for the company. in a report on Tuesday. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Mural Oncology has a consensus rating of “Moderate Buy” and a consensus target price of $13.00.

Mural Oncology Price Performance

MURA stock opened at $1.18 on Wednesday. Mural Oncology has a 12 month low of $1.12 and a 12 month high of $5.02. The company has a market capitalization of $20.33 million, a PE ratio of -0.13 and a beta of 3.66. The firm’s 50-day moving average is $3.72 and its 200 day moving average is $3.57.

Mural Oncology (NASDAQ:MURA) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($2.01) EPS for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same quarter last year, the firm earned ($3.57) EPS. Sell-side analysts forecast that Mural Oncology will post -7.54 EPS for the current fiscal year.

Institutional Trading of Mural Oncology

A number of large investors have recently bought and sold shares of the business. Acorn Capital Advisors LLC acquired a new position in Mural Oncology during the fourth quarter worth about $4,141,000. Point72 Asset Management L.P. acquired a new stake in shares of Mural Oncology during the 3rd quarter worth about $340,000. Raymond James Financial Inc. purchased a new position in shares of Mural Oncology during the fourth quarter valued at approximately $181,000. Virtu Financial LLC purchased a new stake in Mural Oncology in the 4th quarter worth approximately $129,000. Finally, Renaissance Technologies LLC raised its holdings in Mural Oncology by 17.4% in the 4th quarter. Renaissance Technologies LLC now owns 238,465 shares of the company’s stock valued at $768,000 after acquiring an additional 35,403 shares during the last quarter. Institutional investors and hedge funds own 80.21% of the company’s stock.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.